Details of the Drug Reposition

General Information of This Drug (ID: DMEDITW)

Drug Name
MK-1454   DMEDITW

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Squamous head and neck cell carcinom DIS0UVDG 2D60.0 Phase 2 [1]
------------------------------------------------------------------------------------
2 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Solid tumour/cancer DISZR48F 2A00-2F9Z Phase 1 [2]
Lymphoma DISN6V4S 2A80-2A86 Phase 1 [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT04220866) Study of Intratumoral (IT) MK-1454 in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002). U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)